Kidney Week

Abstract: PUB208

Optimizing Renin Angiotensin-Aldosterone System Inhibition (RAASi) for Kidney Function Preservation in Peritoneal Dialysis (PD): A Quality Improvement (QI) Project

Session Information

• Publication Only

Category: Dialysis

• 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

• Aflaki, Mona, University of Toronto, Toronto, Ontario, Canada

Mona Aflaki, MD, PhD

• Ye, Wen Qing Wendy, University of Toronto, Toronto, Ontario, Canada

Wen Qing Wendy Ye, MD, MS

• Zaidi, Fatema, University of Toronto, Toronto, Ontario, Canada

Fatema Zaidi, MD, MSc

• Saad Mohammed, Arifuddin, University of Toronto, Toronto, Ontario, Canada

Arifuddin Saad Mohammed, MBBS

• Shapiro, Joshua, University of Toronto, Toronto, Ontario, Canada

Joshua Shapiro, MD

• Alabdulaaly, May, University of Toronto, Toronto, Ontario, Canada

May Alabdulaaly, MBBS

• Auguste, Bourne L., University of Toronto, Toronto, Ontario, Canada

Bourne L. Auguste, MD, MSc

Background

Preserving residual kidney function is crucial for improving outcomes in PD. RAASi helps preserve kidney function, protect cardiovascular health, and regulate blood pressure (BP). However, it is often discontinued due to concerns about hyperkalemia, and hypotension. Using QI methodology, we explored reasons for discontinuation and developed solutions to improve RAASi in PD patients. We aimed to develop and implement solutions using QI methods to increase the proportion of patients on RAASi.

Methods

We reviewed charts of 54 PD patients at Sunnybrook Health Sciences Centre between July 2022-Sept 2023. Data on RAASi usage, baseline potassium (K), and residual urine output were collected. Root-cause analyses, using surveys and Pareto charts, identified gaps in RAASi usage.

Results

Our analysis revealed only 55% of patients were prescribed a RAASi (Figure 1). The median residual urine volume was 861.8 ± 72.3 mL, and the average serum K was 4.4 ± 0.1 mmol/L. The root-cause analysis identified two reasons for the low prescription: cessation of RAASi before PD initiation and failure to restart therapy. We implemented the PD Passport in electronic medical records to identify patients not on RAASi to ensure monitoring of urine output, serum K, and BP every six months, with initiation of RAASi if appropriate. There was a slight increase in patients on RAASi after the project was announced between July-Sept 2023, suggestive of a possible Hawthorne effect prior to initiation of formal interventions.

Conclusion

The PD Passport, launched in May, aims to increase RAASi use by 20%. We will evaluate its impact on prescription rates, residual urine volume, hyperkalemia, and BP. We demonstrate the feasibility of using QI principles in PD to enhance care. With the PD Passport, we aim to preserve residual kidney function with RAASi, while monitoring patients to maximize benefits and minimize side effects. This initiative promises improved patient outcomes and PD management.